Cargando…

miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling

MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accura...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Shuai, Yang, Mengyuan, Yang, Hao, Chang, Ruimin, Fang, Feng, Yang, Lianyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249243/
https://www.ncbi.nlm.nih.gov/pubmed/30464168
http://dx.doi.org/10.1038/s41389-018-0097-8
_version_ 1783372703008292864
author Xiao, Shuai
Yang, Mengyuan
Yang, Hao
Chang, Ruimin
Fang, Feng
Yang, Lianyue
author_facet Xiao, Shuai
Yang, Mengyuan
Yang, Hao
Chang, Ruimin
Fang, Feng
Yang, Lianyue
author_sort Xiao, Shuai
collection PubMed
description MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accurate role of miR-330-5p in HCC is still uncertain. Here, we report that miR-330-5p expression is upregulated in HCC tissues and cell lines, and is associated with tumor size, tumor nodule number, capsule formation and Tumor Node Metastasis (TNM) stage in HCC patients. Overexpression of miR-330-5p promotes proliferation and growth of HCC cells in vitro and in vivo, while miR-330-5p knockdown has the inverse effect. Moreover, using miRNA databases and dual luciferase report assay, we find miR-330-5p directly binds to the 3′-untranslated region (3′-UTR) of Sprouty2 (SPRY2). Then we find the novel biofunctional role of SPRY2 inactivation in promoting HCC progression. Finally, we confirm that miR-330-5p suppresses SPRY2 to promote proliferation via mitogen-activated protein kinases (MAPK)/extracellular regulated kinase (ERK) signaling in HCC. Taken together, our findings demonstrate the critical role of miR-330-5p in promoting HCC progression via targeting SPRY2 to activate MAPK/ERK signaling, which may provide a novel and promising prognostic marker and therapeutic target for HCC.
format Online
Article
Text
id pubmed-6249243
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62492432018-11-26 miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling Xiao, Shuai Yang, Mengyuan Yang, Hao Chang, Ruimin Fang, Feng Yang, Lianyue Oncogenesis Article MicroRNAs (miRNAs) have been identified as critical modulators of cell proliferation and growth, which are the major causes of cancer progression including hepatocellular carcinoma (HCC). Our previous miRNA microarray data have shown that miR-330-5p was always upregulated in HCC. However, the accurate role of miR-330-5p in HCC is still uncertain. Here, we report that miR-330-5p expression is upregulated in HCC tissues and cell lines, and is associated with tumor size, tumor nodule number, capsule formation and Tumor Node Metastasis (TNM) stage in HCC patients. Overexpression of miR-330-5p promotes proliferation and growth of HCC cells in vitro and in vivo, while miR-330-5p knockdown has the inverse effect. Moreover, using miRNA databases and dual luciferase report assay, we find miR-330-5p directly binds to the 3′-untranslated region (3′-UTR) of Sprouty2 (SPRY2). Then we find the novel biofunctional role of SPRY2 inactivation in promoting HCC progression. Finally, we confirm that miR-330-5p suppresses SPRY2 to promote proliferation via mitogen-activated protein kinases (MAPK)/extracellular regulated kinase (ERK) signaling in HCC. Taken together, our findings demonstrate the critical role of miR-330-5p in promoting HCC progression via targeting SPRY2 to activate MAPK/ERK signaling, which may provide a novel and promising prognostic marker and therapeutic target for HCC. Nature Publishing Group UK 2018-11-21 /pmc/articles/PMC6249243/ /pubmed/30464168 http://dx.doi.org/10.1038/s41389-018-0097-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Xiao, Shuai
Yang, Mengyuan
Yang, Hao
Chang, Ruimin
Fang, Feng
Yang, Lianyue
miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title_full miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title_fullStr miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title_full_unstemmed miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title_short miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
title_sort mir-330-5p targets spry2 to promote hepatocellular carcinoma progression via mapk/erk signaling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249243/
https://www.ncbi.nlm.nih.gov/pubmed/30464168
http://dx.doi.org/10.1038/s41389-018-0097-8
work_keys_str_mv AT xiaoshuai mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling
AT yangmengyuan mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling
AT yanghao mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling
AT changruimin mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling
AT fangfeng mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling
AT yanglianyue mir3305ptargetsspry2topromotehepatocellularcarcinomaprogressionviamapkerksignaling